Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Oropharyngeal Neoplasms 1Mouth Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Carcinoma 1

Interventions

Cisplatin 24pembrolizumab 23Magnetic Resonance Spectroscopy 19Specimen Handling 16Radiotherapy, Intensity-Modulated 12Carboplatin 12Cetuximab 111,2-diaminocyclohexaneplatinum II citrate 10Platinum 9Paclitaxel 9Radiotherapy 6Radiation 6Fluorouracil 6Biopsy 5Taxes 4Nivolumab 4Docetaxel 4(225)Ac-DOTA-c(RGDyK) 4X-Rays 3Pemetrexed 3Fluorodeoxyglucose F18 3reolysin 2pralsetinib 2ipatasertib 2cemiplimab 2atezolizumab 2Surgical Procedures, Operative 2Standard of Care 2Radiotherapy, Image-Guided 2Radiosurgery 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × BAY 1895344 × Head & Neck × Clear all
NCT04576091 2024-12-13

Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
7 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡